Comprehensive Analysis of Amlodipine (DB00381): A Foundational Cardiovascular Therapeutic

Executive Summary

Amlodipine is a third-generation dihydropyridine calcium channel blocker (CCB) that stands as a cornerstone therapy in cardiovascular medicine. Its clinical utility is anchored in its unique pharmacokinetic profile, characterized by a slow onset of action and a long elimination half-life, which translates to sustained, 24-hour blood pressure control with once-daily dosing and a favorable tolerability profile compared to earlier CCBs. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension, chronic stable angina, and vasospastic angina. Furthermore, it holds a specific indication for reducing the risk of hospitalization for angina and the need for coronary revascularization procedures in patients with documented coronary artery disease (CAD). Its versatility is further demonstrated by its extensive use as a foundational component in numerous fixed-dose combination therapies, targeting multiple facets of cardiovascular risk. This report provides an exhaustive analysis of Amlodipine's chemical properties, pharmacological mechanisms, clinical evidence base, safety profile, and its comparative position within the broader class of antihypertensive agents.

---

Section 1: Molecular Profile and Pharmaceutical Formulations

1.1 Chemical Identity and Nomenclature

Amlodipine is a small molecule drug classified chemically as a fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative.[1] Its identity is precisely defined by established chemical and regulatory identifiers.

• Systematic (IUPAC) Name: 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate.[2]
• Primary Identifiers:
• CAS Number (Parent): 88150-42-9, which uniquely identifies the amlodipine free base, the active moiety.[3]
• DrugBank ID: DB00381.[1]
• PubChem CID (Parent): 2162.[3]
• Synonyms: The drug is referred to by various synonyms in scientific literature and international markets, including Amlodipine free base, Amlodipino, and Amlodipinum.[2]

1.2 Physicochemical Properties and Stereochemistry

The therapeutic behavior of amlodipine is rooted in its specific physicochemical and stereochemical characteristics.

• Molecular Formula: C20​H25​ClN2​O5​.[2]
• Molecular Weight (Parent): The average molecular weight of the parent compound is approximately 408.88 g/mol, with a monoisotopic mass of 408.145199627 Da.[2]
• Physical Form: In its solid state, amlodipine is typically handled as a crystalline powder.[3]
• Stereochemistry: Amlodipine is a chiral molecule and is administered clinically as a racemic mixture, containing equal amounts of the (R)- and (S)-enantiomers. The chiral center is located at the C4 position of the dihydropyridine ring. Pharmacological activity resides almost exclusively in the (S)-amlodipine enantiomer, which is a significantly more potent calcium channel blocker than the (R)-amlodipine enantiomer.[7] This stereospecificity is a critical detail, as it has driven research into isomer-specific formulations to potentially improve efficacy and reduce side effects.

1.3 Analysis of Salt Forms: Besylate, Benzoate, and Maleate

The active amlodipine moiety is formulated into various salt forms to enhance its pharmaceutical properties, such as stability and solubility. The choice of salt form is a deliberate pharmaceutical strategy that has enabled the development of different dosage forms to meet specific clinical needs.

• Amlodipine Besylate: This is the most prevalent pharmaceutical salt form and the one used in the original branded product, Norvasc.[8]
• Chemical Name: 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate.[9]
• Identifiers: CAS 111470-99-6; UNII 864V2Q084H.[12]
• Properties: A white crystalline powder with a molecular weight of 567.1 g/mol. It is slightly soluble in water and sparingly soluble in ethanol, properties that are well-suited for the manufacturing of solid oral tablets.[9]
• Amlodipine Maleate: Another salt form documented in chemical databases.
• Identifiers: CAS 88150-47-4; UNII CQ27G2BZJM.[13]
• Properties: Molecular weight of 524.9 g/mol.[13]
• Amlodipine Benzoate: This salt form was specifically developed for use in a liquid formulation.
• Identifiers: CAS 1239916-29-0; UNII XD75TQ8A2P.[14]
• Properties: Molecular weight of 531.0 g/mol. It is the active ingredient in the oral suspension Katerzia.[14] The development of the benzoate salt exemplifies a key aspect of pharmaceutical life-cycle management, where modifying the salt form allows for the creation of novel formulations, such as a stable and palatable liquid, to serve patient populations (e.g., pediatrics, geriatrics, individuals with dysphagia) who cannot use tablets.

1.4 Approved Formulations and Excipients

Amlodipine is available in several FDA-approved dosage forms to accommodate a range of patient needs.

• Oral Tablets: The most common form, available in strengths of 2.5 mg, 5 mg, and 10 mg, typically as the besylate salt.[8]
• Oral Liquid Formulations:
• Oral Solution (1 mg/mL): Marketed as Norliqva, which contains amlodipine besylate.[15]
• Oral Suspension (1 mg/mL): Marketed as Katerzia, which contains amlodipine benzoate.[15]
• Inactive Ingredients (Tablets): Common excipients found in amlodipine besylate tablets include microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate. These components facilitate the tablet's manufacturing, stability, and dissolution.[9]

Property	Amlodipine (Parent)	Amlodipine Besylate	Amlodipine Maleate	Amlodipine Benzoate
CAS Number	88150-42-9 3	111470-99-6 12	88150-47-4 13	1239916-29-0 14
DrugBank ID	DB00381 2	DB00381 (Parent)	DB00381 (Parent)	DB00381 (Parent)
PubChem CID	2162 3	9801598	119565	44481893 14
Molecular Formula	C20​H25​ClN2​O5​ 2	C26​H31​ClN2​O8​S 12	C24​H29​ClN2​O9​	C27​H31​ClN2​O7​ 14
Molecular Weight (g/mol)	408.88 3	567.1 9	524.9 13	531.0 14
Common Brand(s)	N/A (Active Moiety)	Norvasc, Norliqva 19	N/A	Katerzia 16
Solubility Profile	Crystalline Powder 3	Slightly soluble in water 9	N/A	Formulated as suspension 15

---

Section 2: Comprehensive Pharmacological Profile

2.1 Pharmacodynamics: Mechanism of Action at the Calcium Channel

Amlodipine is pharmacologically classified as a Dihydropyridine (DHP) Calcium Channel Blocker (CCB), an Antihypertensive Agent, and a Vasodilator Agent.[2]

• Primary Mechanism: Its therapeutic effects are derived from the inhibition of the transmembrane influx of calcium ions (Ca2+) into vascular smooth muscle and cardiac muscle cells. It accomplishes this by blocking voltage-gated L-type (long-lasting) calcium channels.[2] Experimental data indicate that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites located on the alpha-1 subunit of the channel complex.[9]
• Molecular Targets: The primary molecular targets are the voltage-dependent L-type calcium channel subunits, including alpha-1C (CACNA1C), alpha-1D (CACNA1D), and alpha-1S (CACNA1S).[1] Research also suggests it has inhibitory activity on T-type ( CACNA1I) and N-type (CACNA1B) calcium channels, which may contribute to its broader organ-protective effects.[1]

2.2 Vascular Selectivity and Hemodynamic Effects

A defining characteristic of amlodipine and other DHP CCBs is their marked selectivity for vascular tissue over cardiac tissue.

• Vascular Selectivity: Amlodipine exerts a substantially greater inhibitory effect on vascular smooth muscle cells than on cardiac muscle cells.[2] This selectivity is clinically crucial as it allows for potent vasodilation with minimal direct impact on cardiac contractility or conduction at therapeutic doses.
• Hemodynamic Consequences:
• Vasodilation: By acting directly on vascular smooth muscle, amlodipine causes potent peripheral arterial vasodilation. This leads to a significant reduction in total peripheral resistance (afterload), which is the primary force the heart must pump against.[9]
• Blood Pressure Reduction: The decrease in afterload is the principal mechanism underlying its powerful antihypertensive effect.[9]
• Antianginal Effects: The mechanism for relieving angina is twofold. In chronic stable (exertional) angina, the reduction in afterload decreases cardiac workload and, consequently, myocardial oxygen demand. In vasospastic (Prinzmetal's) angina, it directly inhibits the spasm of coronary arteries, thereby restoring blood flow to the myocardium.[2]
• Cardiac Effects: Due to its high vascular selectivity, amlodipine has negligible negative inotropic (contractility-depressing) effects at standard therapeutic doses. It does not adversely affect sinoatrial (SA) nodal function or atrioventricular (AV) conduction, distinguishing it from non-dihydropyridine CCBs.[9]

2.3 Ancillary Mechanisms: Endothelial Function and Antioxidant Properties

Beyond its primary role as a channel blocker, amlodipine exhibits other beneficial properties.

• Nitric Oxide (NO) Production: Evidence suggests that amlodipine enhances the production of nitric oxide (NO), a powerful endogenous vasodilator. This action complements its direct vasodilatory effect and may confer additional benefits to endothelial health.[2]
• Antioxidant Properties: The molecule possesses inherent antioxidant properties. This may contribute to its organ-protective effects, such as suppressing atherosclerosis, beyond what can be attributed to blood pressure reduction alone.[2]

2.4 Pharmacokinetics: The Clinical Significance of a Long Half-Life

The entire clinical value proposition of amlodipine—its efficacy, tolerability, and dosing convenience—is a direct consequence of its unique pharmacokinetic profile. Its long half-life is the single most important feature differentiating it from earlier CCBs.

• Absorption: After oral administration, amlodipine is slowly absorbed, reaching peak plasma concentrations in 6 to 12 hours. Its absolute bioavailability is high, ranging from 64% to 90%.[23]
• Distribution: It is highly bound to plasma proteins (approximately 93%).[9]
• Metabolism: Amlodipine undergoes extensive hepatic metabolism (approximately 90%) into inactive pyridine metabolites. This metabolism is mediated primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme, a fact that is the lynchpin for most of its clinically significant drug-drug interactions.[6]
• Elimination: Elimination from the plasma is biphasic, characterized by a very long terminal elimination half-life of approximately 30-50 hours.[8]
• Excretion: About 60% of the metabolites and 10% of the parent drug are excreted in the urine.[9]

The long half-life results in a gradual onset of action, which prevents the rapid drop in blood pressure that can cause reflex tachycardia, a problematic side effect of older, short-acting DHPs like nifedipine.[8] Furthermore, the sustained plasma concentrations over a 24-hour period allow for true once-daily dosing, a major driver of patient adherence in the management of chronic conditions like hypertension.[2] This sustained effect also provides a "forgiveness factor" for patients who occasionally miss a dose, maintaining better blood pressure control compared to shorter-acting agents and reflecting a significant advantage in real-world clinical practice.[25]

Parameter	Value	Clinical Implication
Bioavailability (%)	64-90% 24	High and predictable absorption from the gut.
Time to Peak Plasma (Tmax)	6-12 hours 9	Slow absorption contributes to a gradual onset of action, minimizing reflex tachycardia.
Plasma Protein Binding (%)	~93% 9	High binding limits free drug concentration, contributing to a long duration of action.
Metabolism Pathway	Hepatic (CYP3A4) 6	Primary route of elimination; key determinant of drug-drug interactions.
Elimination Half-life (t1/2​)	30-50 hours 9	Allows for true once-daily dosing and provides sustained BP control, even with missed doses.
Excretion Route	Urine (10% parent, 60% metabolites) 9	Primarily cleared by the liver, with renal excretion of inactive metabolites.

---

Section 3: Clinical Efficacy in Approved Indications

3.1 Amlodipine as a First-Line Agent for Hypertension

Amlodipine is firmly established as a primary therapy for managing high blood pressure.

• Indication: It is approved for the treatment of hypertension to lower blood pressure. This effect is clinically proven to reduce the risk of fatal and nonfatal cardiovascular events, most notably strokes and myocardial infarctions.[2]
• Monotherapy: It is effective when used alone as an initial antihypertensive agent.[2] The degree of blood pressure reduction achieved with amlodipine is correlated with the severity of the initial hypertension; patients with moderate hypertension tend to have a greater response than those with mild hypertension.[9]
• Clinical Trials Evidence: Its efficacy has been validated in numerous large-scale clinical trials. The landmark Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) demonstrated that amlodipine was comparable to the thiazide-like diuretic chlorthalidone and the ACE inhibitor lisinopril in preventing major coronary events. However, the trial also noted that amlodipine was associated with a higher risk of developing heart failure compared to chlorthalidone.[29]

3.2 Management of Chronic Stable and Vasospastic Angina

Amlodipine is a key agent in the management of myocardial ischemia.

• Chronic Stable Angina: It is indicated for the symptomatic treatment of chronic stable angina. Its efficacy in this setting stems from its ability to reduce afterload, which decreases cardiac workload and myocardial oxygen demand during exertion.[2]
• Vasospastic (Prinzmetal's) Angina: It is indicated for the treatment of both confirmed and suspected vasospastic angina.[1] It acts by directly inhibiting the spasm of coronary arteries. Systematic reviews have confirmed its potency in reducing episodes of vasospastic angina.[30]

3.3 Role in Angiographically Documented Coronary Artery Disease (CAD)

The clinical utility of amlodipine extends beyond symptomatic relief to preventative therapy. This evolution from treating symptoms to modifying disease outcomes represents a significant elevation of its therapeutic status.

• Indication: In a specific subset of patients—those with recently angiographically documented CAD who do not have heart failure or a left ventricular ejection fraction less than 40%—amlodipine is indicated to reduce the risk of two key outcomes: hospitalization due to angina and the need for coronary revascularization procedures.[2] This indication was likely established through a dedicated cardiovascular outcomes trial that demonstrated a benefit in modifying the natural history of the disease process, not just its symptoms.

3.4 Application in Special Populations

Dosage adjustments are recommended to ensure safety and efficacy in specific patient groups.

• Geriatric and Fragile Patients: A lower initial dose of 2.5 mg once daily is recommended. Elderly patients may have reduced clearance and higher plasma concentrations, necessitating a more cautious approach to dosing.[8]
• Patients with Hepatic Impairment: Amlodipine is extensively metabolized by the liver. In patients with severe hepatic impairment, the plasma elimination half-life is significantly prolonged (to approximately 56 hours). Therefore, dose titration must be performed slowly, starting at 2.5 mg daily.[8]
• Pediatric Use (Ages 6-17): For children and adolescents, the effective oral dose for hypertension is 2.5 mg to 5 mg once daily. Doses exceeding 5 mg per day have not been studied in this population. The effects of amlodipine in children under the age of 6 are not known.[28]

---

Section 4: The Central Role of Amlodipine in Combination Therapy

While effective as a monotherapy, amlodipine has evolved to become the backbone of modern antihypertensive combination strategies. The vast number of clinical trials investigating amlodipine in combination with nearly every other class of cardiovascular medication underscores its role as a reliable, default partner drug. Its predictable pharmacokinetics, well-understood safety profile, and complementary mechanism of action make it an ideal candidate to combine with other agents, cementing its clinical indispensability.

4.1 Synergies with Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

Combining a peripheral vasodilator like amlodipine with an agent that blocks the RAAS pathway provides a powerful, multi-pronged approach to blood pressure control. This combination offers synergistic efficacy and can also mitigate side effects; for instance, RAAS inhibitors can counteract the dose-dependent edema associated with amlodipine. Amlodipine has been extensively studied in clinical trials with:

• Angiotensin II Receptor Blockers (ARBs): Including valsartan, losartan, telmisartan, olmesartan, irbesartan, candesartan, fimasartan, and allisartan.[31]
• ACE Inhibitors: Including lisinopril, perindopril, enalapril, and benazepril.[5]
• Direct Renin Inhibitors: Including aliskiren.[33]

4.2 Combination with Diuretics and Other Antihypertensives

• Diuretics: Often incorporated into triple-therapy regimens, diuretics add a volume-reduction mechanism to the vasodilation and RAAS blockade. Key diuretic partners in clinical trials include hydrochlorothiazide (HCTZ) and indapamide.[31]
• Beta-Blockers: Combinations with beta-blockers such as bisoprolol and acebutolol have also been evaluated.[33]

4.3 Fixed-Dose Combinations for Comprehensive Cardiovascular Risk Management

The development of fixed-dose combinations, or "polypills," represents a major advance in cardiovascular risk management. By combining amlodipine with a statin in a single tablet, these products improve patient adherence while simultaneously targeting two of the most critical risk factors: hypertension and dyslipidemia. Amlodipine has been studied and marketed in combination with atorvastatin and rosuvastatin for this purpose.[2]

4.4 Synthesis of Evidence from Key Combination-Therapy Trials

The clinical development of amlodipine as a combination agent is extensive, spanning numerous trials with various designs and objectives. Phase 2 trials typically focus on dose-finding and establishing initial efficacy [33], while larger Phase 3 trials are designed to confirm efficacy and safety in broader populations.[32] The sheer volume of these studies, including those for fixed-dose products like Amlodipine/Valsartan (NCT01001572), Amlodipine/Perindopril (NCT01556997), and triple therapies like Amlodipine/Olmesartan/HCTZ (NCT00902538), highlights its central role in multi-drug strategies for hypertension.

Trial Identifier	Phase	Status	Combination Agents	Therapeutic Area	Key Purpose/Rationale
NCT01835418 31	N/A	Unknown	Amlodipine, Lisinopril	Hypertension	Treatment; comparing bedtime administration of the two agents.
NCT01518998 33	2	Completed	Amlodipine, Fimasartan	Essential Hypertension	Treatment; evaluating efficacy and safety of the combination.
NCT00220220 34	3	Completed	Amlodipine, Olmesartan	Hypertension	Treatment; evaluating amlodipine as an add-on therapy to olmesartan.
NCT05476354 34	3	Completed	Amlodipine, Irbesartan	Essential Hypertension	Treatment; evaluating efficacy and safety of the combination therapy.
NCT03156842 34	3	Completed	Amlodipine, Fimasartan, Rosuvastatin	Hypertension & Dyslipidemia	Treatment; evaluating a triple-combination polypill.
NCT02969265 32	3	Withdrawn	Amlodipine, Candesartan	Essential Hypertension	Treatment; evaluating a fixed-dose combination.

---

Section 5: Safety, Tolerability, and Risk Management

5.1 Profile of Adverse Drug Reactions (ADRs)

Amlodipine is generally well-tolerated. Most adverse reactions are mild to moderate in severity and are often predictable based on its mechanism of action.[8]

• Common, Dose-Related ADRs: The most frequently reported side effects are headache and peripheral edema (swelling of the ankles and feet). Both are directly related to the dose of amlodipine administered.[8] The edema is a direct, on-target pharmacological consequence of the drug's potent arteriolar vasodilation. By relaxing the arterioles without a corresponding relaxation of the venules, it increases hydrostatic pressure in the precapillary bed, forcing fluid into the interstitial space.[22] Understanding this mechanism explains why the effect is dose-dependent and why it can be mitigated by co-administration of drugs that promote venodilation, such as ACE inhibitors or ARBs.[24]
• Other Common ADRs (>1%): Other commonly reported adverse experiences include fatigue, nausea, abdominal pain, and somnolence (drowsiness).[8] User-reported data also frequently mention dizziness, anxiety, and palpitations.[35]
• Less Common/Postmarketing ADRs: A broader range of adverse events has been reported in postmarketing surveillance. These include, but are not limited to: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypoesthesia, peripheral neuropathy, paresthesia, tremor, vertigo, constipation, pancreatitis, gingival hyperplasia, arthralgia, muscle cramps, insomnia, depression, and dyspnea.[8]

5.2 Clinically Significant Drug and Food Interactions

Most of amlodipine's drug interactions are related to its metabolism via the CYP3A4 enzyme system.

• CYP3A4 Inhibitors: Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) can significantly increase the plasma concentration of amlodipine, raising the risk of hypotension and other side effects. Dose monitoring and potential dose reduction are recommended.[8]
• CYP3A4 Inducers: Co-administration with inducers of CYP3A4 (e.g., rifampin) can decrease amlodipine plasma levels, potentially leading to a loss of therapeutic efficacy.[8]
• Grapefruit Juice: While caution is generally advised for CCBs, one study in healthy volunteers found that co-administration of 240 mL of grapefruit juice did not have a significant effect on the pharmacokinetics of amlodipine.[8]
• Other Drugs: In clinical trials, amlodipine has been safely administered with a wide range of common cardiovascular medications, including thiazide diuretics, beta-blockers, ACE inhibitors, long-acting nitrates, digoxin, warfarin, and non-steroidal anti-inflammatory drugs (NSAIDs).[11]

5.3 Contraindications, Warnings, and Precautions

• Contraindications: Amlodipine is contraindicated in patients with a known hypersensitivity or allergy to amlodipine or any of its formulation components.[8]
• Warnings and Precautions:
• Hypotension: Symptomatic hypotension can occur, particularly in patients with severe aortic stenosis. However, due to the gradual onset of action, acute hypotension is unlikely.[8]
• Increased Angina or Myocardial Infarction: Rarely, worsening angina or acute myocardial infarction can develop after initiating or increasing the dose of amlodipine, especially in patients with severe obstructive coronary artery disease.[8]
• Hepatic Failure: As the drug is extensively metabolized by the liver, it must be used with caution and titrated slowly in patients with severe hepatic impairment.[8]

5.4 Toxicology and Overdose Management

• Overdose: Overdosage is expected to cause excessive peripheral vasodilation, leading to marked and potentially prolonged systemic hypotension.
• Management: Treatment is supportive and includes monitoring of cardiovascular and respiratory function, elevation of the extremities, and management of circulating fluid volume. If there are no contraindications, a vasoconstrictor may be administered to restore vascular tone and blood pressure. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.
• GHS Hazard Statements: For the parent compound, globally harmonized system hazard statements include H301 (Toxic if swallowed), H318 (Causes serious eye damage), and H373 (May cause damage to organs through prolonged or repeated exposure).[37]

---

Section 6: Amlodipine in Context: A Comparative Analysis

Amlodipine's clinical value is best understood when compared to other major classes of calcium channel blockers. Its development addressed key limitations of both earlier dihydropyridines and the non-dihydropyridine agents, resulting in an optimized profile for the treatment of hypertension.

6.1 Pharmacokinetic and Pharmacodynamic Comparison: Amlodipine vs. Nifedipine

• Class: Both amlodipine and nifedipine are dihydropyridine CCBs.[21]
• Pharmacokinetics: The most critical difference lies in their half-lives. Amlodipine possesses an inherently long elimination half-life of 30-50 hours. In contrast, nifedipine has a very short half-life, necessitating sophisticated extended-release (ER or GITS) formulations to permit once-daily dosing.[23]
• Clinical Implications: This pharmacokinetic difference has profound clinical implications. Amlodipine provides smoother, more consistent blood pressure control over a 24 to 48-hour period and is significantly more "forgiving" of a missed dose than nifedipine GITS.[25] Nifedipine, even in its GITS formulation, can exhibit a more pronounced peak-to-trough effect in blood pressure, which is not observed with amlodipine.[38]
• Side Effects: Short-acting formulations of nifedipine are notorious for causing rapid vasodilation, leading to reflex tachycardia, flushing, and hypotension. While ER formulations mitigate this, amlodipine's gradual onset inherently provides a better tolerability profile. Amlodipine is more commonly associated with headache and dose-dependent edema, while nifedipine is more likely to cause flushing and dizziness.[38] Overall, amlodipine is generally considered better tolerated.[38]

6.2 Dihydropyridine vs. Non-Dihydropyridine: Amlodipine vs. Diltiazem

• Class: Amlodipine is a dihydropyridine (DHP), whereas diltiazem is a non-dihydropyridine (non-DHP) of the benzothiazepine class.[21]
• Mechanism & Selectivity: This class difference dictates their site of action. Amlodipine is a more potent peripheral vasodilator with high vascular selectivity. Diltiazem has a more mixed effect, acting on both vascular smooth muscle and the myocardium. It has more pronounced negative chronotropic and dromotropic effects, depressing the heart rate and slowing conduction through the SA and AV nodes.[21]
• Efficacy in Hypertension: In a head-to-head clinical trial in patients with mild to moderate hypertension, amlodipine was found to produce significantly greater reductions in both systolic and diastolic blood pressure compared to a long-acting formulation of diltiazem.[39]
• Side Effects: Their side effect profiles reflect their differing selectivity. Amlodipine is more likely to cause side effects related to vasodilation, such as edema and headache. Diltiazem is more likely to cause cardiac side effects like bradycardia and AV block, as well as constipation. Diltiazem is also associated with a greater number of potential drug interactions.[35]

6.3 A Synthesis of Comparative Efficacy and Tolerability

The comparative data position amlodipine as a highly optimized CCB, particularly for its primary indication of hypertension. First-generation DHPs like nifedipine were effective vasodilators but were limited by short half-lives, inconvenient dosing, and adverse hemodynamic effects like reflex tachycardia. Non-DHPs like diltiazem offered rate control but were less potent as vasodilators and carried a risk of cardiodepressive effects, limiting their use in patients with certain comorbidities. Amlodipine's development effectively solved this therapeutic dilemma. Its long half-life and gradual onset of action eliminated the reflex tachycardia associated with older DHPs, while its high vascular selectivity avoided the significant cardiodepressive effects of the non-DHP class. It thus retains the potent vasodilatory benefit of the DHP class while minimizing the key drawbacks of both older DHPs and the non-DHP agents, making it an ideal agent for lowering blood pressure without compromising cardiac function in the majority of patients.

Feature	Amlodipine	Nifedipine (ER/GITS)	Diltiazem (ER)
Drug Sub-Class	Dihydropyridine (DHP) 2	Dihydropyridine (DHP) 21	Non-DHP (Benzothiazepine) 21
Primary Site of Action	Peripheral Arteries 9	Peripheral Arteries 40	Peripheral Arteries & Heart 38
Elimination Half-Life	30-50 hours (long) 9	~2-5 hours (short, requires ER formulation) 38	~3.5-9 hours (requires ER formulation) 35
Dosing Frequency	Once Daily 2	Once Daily (ER form) 38	Once or Twice Daily (ER form) 35
Potency (Vasodilation)	High 9	High 40	Moderate 29
Effect on Heart Rate	Minimal / None 9	Can cause reflex tachycardia (less with ER) 21	Decreases 22
Effect on AV Conduction	Minimal / None 9	Minimal / None 38	Slows 22
Key Side Effects	Edema, Headache 8	Flushing, Dizziness, Edema 38	Bradycardia, Constipation, Edema 35
Primary Use Case	Hypertension, Angina 2	Angina, Hypertension 41	Angina, Hypertension, Arrhythmias 35

---

Section 7: Regulatory History and Concluding Synthesis

7.1 Timeline of Key Regulatory Milestones

The regulatory history of amlodipine is a case study in successful pharmaceutical life-cycle management, demonstrating a strategic evolution from a novel monotherapy to a foundational component of modern cardiovascular care.

• Initial Approval: Amlodipine besylate, under the brand name Norvasc, was first approved by the US FDA in 1987.[2] Some sources cite a 1992 approval date, which may refer to a final marketing approval or approval in other jurisdictions.[12]
• Label Expansions: Following its initial approval, the drug's label was expanded based on new clinical trial data. A notable supplemental new drug application (sNDA) was approved in 1996, likely related to its indication in coronary artery disease.[44] This strategic investment in further research allowed the drug to be differentiated from competitors with a value-added, evidence-based claim for risk reduction.
• Combination Product Approvals: As the patent on the parent molecule approached expiration, a new wave of innovation focused on creating patent-protected fixed-dose combinations. This leveraged the established reputation of amlodipine to create new branded products. Key approvals include:
• Caduet (amlodipine/atorvastatin): Approved in 2004 for treating both hypertension and hyperlipidemia.[45]
• Azor (amlodipine/olmesartan): Approved in 2007 for hypertension.[46]
• New Formulation Approvals: Even decades after its initial launch, new formulations were developed to serve niche markets and extend the drug's clinical utility. These include:
• Katerzia (amlodipine benzoate oral suspension): Approved in 2019.[14]
• Norliqva (amlodipine besylate oral solution): Also approved to serve patients unable to take tablets.[16]

This multi-stage process—establish, expand, combine, and reformulate—demonstrates a highly effective strategy for maximizing the clinical and commercial value of a cornerstone molecule over several decades.

7.2 Expert Synthesis: Amlodipine's Enduring Legacy and Place in Therapy

Amlodipine's ascent to and persistence as a leading cardiovascular medication is not accidental. It is fundamentally rooted in a superior and intentionally designed pharmacokinetic profile that translates directly into tangible clinical advantages: potent, smooth, and sustained blood pressure control; an excellent tolerability profile that avoids the major pitfalls of older agents; and the convenience of true once-daily dosing that promotes patient adherence.

Its well-defined safety profile and complementary mechanism of action have made it an indispensable component of modern combination therapy strategies, allowing clinicians to target multiple pathophysiological pathways in the management of comprehensive cardiovascular risk. Despite being a molecule developed in the 1980s, its continuous study, integration into novel fixed-dose combinations, and development of new patient-friendly formulations ensure its enduring relevance. Amlodipine's journey serves as a paradigm of rational drug design and strategic life-cycle management, securing its legacy as a foundational and indispensable drug in the cardiovascular pharmacopeia.

Works cited

1. Amlodipine Gene Set - Ma'ayan Laboratory, Computational Systems Biology, accessed July 11, 2025, [https://maayanlab.cloud/Harmonizome/gene\_set/Amlodipine/DrugBank\+Drug\+Targets]
2. Amlodipine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 11, 2025, [https://go.drugbank.com/drugs/DB00381]
3. CAS RN 88150-42-9 - Fisher Scientific, accessed July 11, 2025, [https://www.fishersci.com/us/en/browse/cas/88150\-42\-9]
4. 4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate - PubChem, accessed July 11, 2025, [https://pubchem.ncbi.nlm.nih.gov/substance/56313574]
5. Amlodipine - brand name list from Drugs.com, accessed July 11, 2025, [https://www.drugs.com/ingredient/amlodipine.html]
6. KEGG DRUG: Amlodipine, accessed July 11, 2025, [https://www.genome.jp/dbget\-bin/www\_bget?D07450\+D00615\+D02914]
7. (R)-Amlodipine | C20H25ClN2O5 | CID 9801597 - PubChem, accessed July 11, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/R\_\-Amlodipine]
8. Norvasc (amlodipine besylate) tablets label - accessdata.fda.gov, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/019787s047lbl.pdf]
9. 69-4782-00-2 Norvasc® (amlodipine besylate) Tablets DESCRIPTION CLINICAL PHARMACOLOGY - accessdata.fda.gov, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2005/019787s037lbl.pdf]
10. 70-4782-00- Norvasc® (amlodipine besylate) Tablets DESCRIPTION CLINICAL PHARMACOLOGY - accessdata.fda.gov, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2005/019787s038lbl.pdf]
11. 19787-S017 Norvase Tablets Approval - accessdata.fda.gov, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2000/19787\-s017\_norvase.pdf]
12. Amlodipine Besylate | C26H31ClN2O8S | CID 60496 - PubChem, accessed July 11, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/Amlodipine\-Besylate]
13. Amlodipine Maleate | C24H29ClN2O9 | CID 6435922 - PubChem, accessed July 11, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/Amlodipine\-Maleate]
14. Amlodipine Benzoate | C27H31ClN2O7 | CID 44481893 - PubChem, accessed July 11, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/44481893]
15. Amlodipine (Norvasc, Katerzia, Norliqva): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed July 11, 2025, [https://www.webmd.com/drugs/2/drug\-5891/amlodipine\-oral/details]
16. Amlodipine: Uses, Side Effects & Dosage - Drugs.com, accessed July 11, 2025, [https://www.drugs.com/amlodipine.html]
17. Amlodipine Besylate - FDA Approval - MedPath, accessed July 11, 2025, [https://trial.medpath.com/drug/approvals/fda/e5b336a4c6454126]
18. Norvasc® - accessdata.fda.gov, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/pediatric/Amlodipine.pdf]
19. Amlodipine (oral route) - Mayo Clinic, accessed July 11, 2025, [https://www.mayoclinic.org/drugs\-supplements/amlodipine\-oral\-route/description/drg\-20061784]
20. Major differences among the three classes of calcium antagonists, accessed July 11, 2025, [https://academic.oup.com/eurheartj/article\-pdf/18/suppl\_A/56/1377801/18\-suppl\_A\-56\.pdf]
21. Calcium channel blockers for hypertension: old, but still useful, accessed July 11, 2025, [https://www.e\-jcpp.org/journal/view.php?number\=79]
22. Calcium channel antagonists - Australian Prescriber, accessed July 11, 2025, [https://australianprescriber.tg.org.au/articles/calcium\-channel\-antagonists.html]
23. Pharmacokinetics of calcium antagonists - PubMed, accessed July 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/2467122/]
24. Amlodipine - Wikipedia, accessed July 11, 2025, [https://en.wikipedia.org/wiki/Amlodipine]
25. comparative crossover evaluation of amlodipine and nifedipine gits before and after a missed dose: 48-h blood pressure profiles | American Journal of Hypertension | Oxford Academic, accessed July 11, 2025, [https://academic.oup.com/ajh/article/15/6/580/414125]
26. Full article: Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS - Taylor & Francis Online, accessed July 11, 2025, [https://www.tandfonline.com/doi/full/10\.3109/08037051\.2012\.690615]
27. Diltiazem Vs Amlodipine - Consensus Academic Search Engine, accessed July 11, 2025, [https://consensus.app/questions/diltiazem\-vs\-amlodipine/]
28. Norvasc (amlodipine besylate) tablet label - accessdata.fda.gov, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2013/019787s054lbl.pdf]
29. Calcium Channel Blockers Review - Medicaid.nv.gov, accessed July 11, 2025, [https://www.medicaid.nv.gov/Downloads/provider/NVRx\_DCR\_20090326\_Calcium\_Channel\_Blockers.pdf]
30. Comparison of various calcium antagonist on vasospastic angina: a systematic review, accessed July 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/36634997/]
31. Hypertension Unknown Status Phase Trials for Amlodipine (DB00381) | DrugBank Online, accessed July 11, 2025, [https://go.drugbank.com/indications/DBCOND0020037/clinical\_trials/DB00381?status\=unknown\_status]
32. Hypertensive Withdrawn Phase 3 Trials for Amlodipine (DB00381) | DrugBank Online, accessed July 11, 2025, [https://go.drugbank.com/indications/DBCOND0046062/clinical\_trials/DB00381?phase\=3\&status\=withdrawn]
33. Hypertensive Diseases Completed Phase 2 Trials for Amlodipine (DB00381) - DrugBank, accessed July 11, 2025, [https://go.drugbank.com/indications/DBCOND0084664/clinical\_trials/DB00381?phase\=2\&status\=completed]
34. Hypertension,Essential Completed Phase 3 Trials for Amlodipine (DB00381) - DrugBank, accessed July 11, 2025, [https://go.drugbank.com/indications/DBCOND0086660/clinical\_trials/DB00381?phase\=3\&status\=completed]
35. Amlodipine vs Diltiazem Comparison - Drugs.com, accessed July 11, 2025, [https://www.drugs.com/compare/amlodipine\-vs\-diltiazem]
36. Amlodipine vs Nifedipine Comparison - Drugs.com, accessed July 11, 2025, [https://www.drugs.com/compare/amlodipine\-vs\-nifedipine]
37. Amlodipine | Calcium Channel Blocker | AmBeed.com, accessed July 11, 2025, [https://www.ambeed.com/products/88150\-42\-9\.html]
38. What is the difference between nifedipine and amlodipine? - Dr.Oracle AI, accessed July 11, 2025, [https://www.droracle.ai/articles/6954/difference\-between\-nifedipine\-and\-amlodipine]
39. Comparison of Amlodipine and Long-Acting Diltiazem in the Treatment of Mild or Moderate Hypertension - Oxford Academic, accessed July 11, 2025, [https://academic.oup.com/ajh/article/10/11/1263/149251]
40. The Effect of Topical Nifedipine versus Diltiazem on the Acute Anal ..., accessed July 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10404091/]
41. Comparing Diltiazem vs Nifedipine - Drugs.com, accessed July 11, 2025, [https://www.drugs.com/compare/diltiazem\-vs\-nifedipine]
42. Amlodipine - StatPearls - NCBI Bookshelf, accessed July 11, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK519508/]
43. www.ncbi.nlm.nih.gov, accessed July 11, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK519508/\#:\~:text\=Amlodipine%20is%20an%20oral%20dihydropyridine,approved%20amlodipine%20besylate%20in%201987\.]
44. Drug Approval Package: Norvasc (Amlodipine Besylate) NDA# 19-787/S007, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/nda/96/19\-787s007\_Amlodipine.cfm]
45. Drug Approval Package: Caduet (amlodipine besylate/atorvastatin calcium) NDA #021540, accessed July 11, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2004/021540S000\_Caduet.cfm]
46. Azor (amlodipine and olmesartan) FDA Approval History - Drugs.com, accessed July 11, 2025, [https://www.drugs.com/history/azor.html]
47. Is Amlodipine approved by the FDA? - Patsnap Synapse, accessed July 11, 2025, [https://synapse.patsnap.com/blog/is\-amlodipine\-approved\-by\-the\-fda]